Publication Name	World Journal of Gastroenterology
Manuscript ID	5169
Country	Italy

Received	2013-08-20 08:39
Peer-Review Started	2013-08-20 16:13
To Make the First Decision	2013-09-27 16:49
Return for Revision	2013-09-30 10:27
Revised	2013-10-16 02:57
Second Decision	2013-10-21 17:38
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2013-10-22 07:44
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-12-17 11:09
Publish the Manuscript Online	2014-01-14 20:11

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Transplantation
Manuscript Type	Topic Highlights
Article Title	Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients
Manuscript Source	Invited Manuscript
All Author List	Alessio Provenzani, Andrew Santeusanio, Erin Mathis, Monica Notarbartolo, Manuela Labbozzetta, Paola Poma, Ambra Provenzani, Carlo Polidori, Giovanni Vizzini, Piera Polidori and Natale D'Alessandro
Funding Agency and Grant Number
Corresponding Author	Alessio Provenzani, PharmD, PhD, Department of Clinical Pharmacy, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT), via E. Tricomi n. 5, 90127 Palermo, Italy. aprovenzani@ismett.edu
Key Words	Pharmacogenetics; Calcineurin inhibitors; Tacrolimus; Liver transplant; Kidney transplant; Single nucleotide polymorphisms; CYP3A4; CYP3A5; ABCB1
Core Tip	As researchers continue to evaluate the influence of single nucleotide polymorphisms on tacrolimus dosing and on the response to the drug, the challenge now becomes to assess the potential clinical implications of this research for medical practice. Sufficient data have been accumulated to be certain that the liver donor and kidney recipient CYP3A5 genotype has an important influence on tacrolimus dosing and on the observed blood trough levels of the drug. However, the question remains, should genotyping become a standard of practice in transplantation?
Publish Date	2014-01-14 20:11
Citation	Provenzani A, Santeusanio A, Mathis E, Notarbartolo M, Labbozzetta M, Poma P, Provenzani A, Polidori C, Vizzini G, Polidori P, D’Alessandro N. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. World J Gastroenterol 2013; 19(48): 9156-9173
URL	http://www.wjgnet.com/1007-9327/full/v19/i48/9156.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i48.9156

Full Article (PDF)	WJG-19-9156.pdf
Manuscript File	5169-Review.doc
Answering Reviewers	5169-Answering reviewers.pdf
Copyright License Agreement	5169-Copyright assignment.pdf
Peer-review Report	5169-Peer review(s).pdf
Scientific Editor Work List	5169-Scientific editor work list.doc